Methylation Analysis Opportunity Identification for Ultra-Sensitive Detection Platform
Research Tools
25
4
5
Target Identification
Objective
A leader in research tools and clinical diagnostic development asked us to evaluate the opportunity for an ultrasensitive detection platform in methylation analysis
Our Approach
Secondary Research
- Compiled information on technology types relevant to methylation analysis, including their key value propositions and limitations; Pulled insights from public literature regarding new and emerging technologies/players in methylation analysis
Primary Research
- Conducted 25 in-depth stakeholder interviews with U.S.-based experts in methylation analysis, including clinical, industry, and academic research backgrounds; ensured all experts could speak to personal experience with methylation analysis testing and awareness of broader landscape trends
Quantitative Analysis
- Built a comprehensive, 5-year model for the methylation analysis market, able to be analyzed / segmented via competitor, technology type (i.e., NGS, PCR, Microarrays, Other), disease area (i.e., Oncology, Immunology, Aging, Neurology, Transplant Rejection, Other), and application area (i.e., Early Detection, MRD, Other)
Outcome
DeciBio
charactered the current and future methylation analysis landscape, defining primary use cases and users as well as key pain points with current technologies
prioritized application areas for the client’s specific detection platform based on the platform’s unique value proposition and technical specifications
built a 5-year model to project the market size and client’s market share in the methylation analysis market
Related Client Results
Sequencing Technology Go-to-Market Strategy
Voice-of-Customer Research
Go-to-Market Strategy
Pricing Strategy
Competitive Analysis
Genetic Testing Company Assessment
Target Identification
RNA-based Oncology Biomarker Market Landscape
Voice-of-Customer Research
Competitive Analysis
Customer Segmentation
